Navigation Links
Reportlinker Adds Outsourcing Preclinical Studies to China

NEW YORK, Oct. 26 /PRNewswire/ -- announces that a new market research report is available in its catalogue.

Reportlinker Adds Outsourcing Preclinical Studies to China

Within the past several years, a number of government labs as well as private and joint venture CRO's have or will soon offer preclinical GLP study services to Western clients. This report, built on discussions and facility visits to the most advanced labs, provides a detailed view of the current and evolving preclinical study capabilities in China, their structures and services, as well as an analysis of the comparative costs between US and China-based CRO's.

  • Strategies being used by small, medium, and large pharmas in China
  • FDA's willingness to accept preclinical data from Chinese labs
  • Advantages of conducting non-human primate studies in China
  • The importance of due diligence and project monitoring
  • Options for managing China programs without an in-country presence

Outsourcing Preclinical Studies to China: Benefits and Challenges reviews the state of preclinical study services in China to identify the current level and near-term trends for compliance with Western GLP standards. Competition to supply CRO services is beginning to cause consolidation and attrition within China. A small number of key preclinical service providers, identified and profiled in this report, have emerged as strong CRO providers. Background material for this report was obtained through discussions with executives and facility visits in China. A detailed cost comparison between China and US-based CRO's shows that study savings of between 35-50% are achievable and that these savings are likely to continue through 2012.

The cost savings associated with using CRO preclinical services in China are discussed in this report in the context of organizational and operational differences between CRO's based in the West and in China. A number of factors are presented that study sponsors must consider before committing to a Chinese CRO. Small- and medium-sized companies can make their preclinical studies budget go further by using China-based CRO's through appropriate due diligence and upfront project planning. FDA and EU regulators have accepted preclinical data generated by China-based CRO's as described in the report, and the FDA has begun to build a resident inspector network in China.

This report describes the impact that language skills and the shortages of key disciplines have on how best to structure preclinical studies in China. Also evaluated are the broad issues such as IP protection and CRO ownership as well as laboratory animal rights regulations. CRO's in China have access to large non-human primate breeding facilities and offer a clear advantage to those companies planning non-human primate studies. The report discusses the several Western laboratory mice, rat, and beagle dog vendors and well as feed providers operating in China.

Outsourcing Preclinical Studies to China: Benefits and Challenges presents an analysis of the current and near-term state of preclinical services available in China. The report begins with a short introduction to the evolution of preclinical services as well as a description of the three laboratory ownership categories. Chapter 2 presents the differences in organizational and operational structures, business practices, as well as personnel shortages and infrastructure issues. Chapter 3 provides a cost case study comparing preclinical study cost between the US and China. Chapter 4 provides a discussion of possible caveats and due diligence factors to be considered when considering placing a preclinical study in China. Chapter 5 provides profiles covering operations, facilities and services of the eleven most advanced CRO's in China.

About the Author: Eric A. Meyers, MBA, is a consultant to the drug development and medical device industries. His 20 years in the healthcare industry includes senior management positions with Fortune 50 companies and successful startups. Mr. Meyers is a recognized expert in drug development sectors in China and India, leading projects to assist both small and large pharmaceutical companies with their Asia drug development strategies. Mr. Meyers received both an MBA and a B.A. from Harvard University.


1.1. Why China: The Current High Level Perspective

1.2 Why China: Motivation and Strategic Considerations for Assessing the China Opportunity

1.3. Why China: Emergence of the Preclinical CRO Sector

1.4. Why China: Trends in Safety Science Services and China's Role

1.5. Report Background and Content


2.1. Overview

Organizational History

High Profile Laboratories

SFDA Accreditation

SFDA vs. US/OECD GLP Standards

2.2. Industry Structure and Competitive Dynamics


Private Labs

Additional Observations

2.3. Industry Infrastructure

Language and Communication

Protection of Intellectual Property Rights and Confidential



Lab Space

Lab Automation Systems


2.4. GLP Compliance

2.5. FDA Acceptance of Data, Laboratory Inspections

2.6. Human Resources, Key Job Categories, and Workforce Stability

Examples of Personnel Limitations


Laboratory Animal Health

2.7. Animal Husbandry and Supply

Laboratory Animal Welfare

Animal Supply

Non-Human Primate (NHP) Studies


3.1. Comparison Cost Examples

3.2. Management Oversight

3.3. Study Pricing

Pricing Case Study

Price Sustainability


4.1. Important Factors for Consideration

Total Cost Elements

Range of Services


Study Management and Oversight

Third Party Option.

Laboratory Ownership

Business Attitude

Managing Regulatory Risk

Closing Comment


5.1. Introduction



5.2. Laboratory Profiles

Bridge Laboratories--Beijing

Summary and Background Information



Beijing Join--Beijing

Summary and Background Information

BioDuro--National Center for Safety Evaluation of

Drugs National Institute for the Control of Pharmaceutical

& Biological Products (NCSED)

Summary and Background Information



National Beijing Center for Drug Safety Evaluation and

Research/IPT (NBCDSER)--MicroConstants China

Summary and Background Information




Shenyang Chemical Industry Research Institute, Safety

Evaluation Center (aka National Shenyang Center for Safety

Evaluation of New Drug--NCDSE & PSEC)

Summary and Background Information


National Chengdu Center for Safety Evaluation of Drugs

(NCCSED)--Frontier BioSciences (NCCSED is also known

as the West China-Frontier Pharmatech Co. Ltd.)

Summary and Background Information




Charles River Labs--China (formed as part of the Charles

River Labs JV with Shanghai BioExplorer Co., Ltd.)

Summary and Background Information



National Shanghai Center for New Drug Safety Evaluation

& Research (NCDSER), Zhangjiang Hi-Tech Park

Summary and Background Information



Medicilon-MPI, Zhangjiang Hi-Tech Park

Summary and Background Information



WuXi AppTec, Wuzhong District, Suzhou, Jiangsu Province

(1-1.5 hours from Shanghai)

Summary and Background Information



ShangPharma, Zhangjiang Hi-Tech Park

Summary and Background Information


SNBL China

Summary and Background Information

References and Notes


Table 3.1. Provides Cost Comparison for Sub-chronic Rat Studies and

Chronic Monkey Studies

Table 3.2. Cost Elements for System-to-Model Toxicology Costs

Table 3.3. Cost Comparison for Preclinical Safety Testing--US vs.. China

Table 3.4. Comparison of Cost Elements for Preclinical Studies--

China vs.. US.


Figure 1.1. Timeline of Major Developments in the Preclinical Safety Sector

Figure 2.1. Western GLP Compliance Distribution in China and US

Figure 3.1. Cost Comparisons--6 Month NHP GLP Studies

Figure 3.2. Cost Comparisons--1-Month Rat GLP Studies

Figure 4.1. Relative risk points associated with a typical IND submission

To order this report:

Reportlinker Adds Outsourcing Preclinical Studies to China

More market research reports here!

    Contact Nicolas Bombourg
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker

SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors
2. Reportlinker Adds Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile
3. Reportlinker Adds Allergan Inc.: PharmaVitae Profile
4. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
5. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
6. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
7. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
8. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
9. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
10. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
11. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
Post Your Comments:
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical Device ... 22 nd April 2016. --> --> ... --> -->   --> --> ... population and the government back up, the Medical Device is one of the ... . With the aging population and the government back up, the Medical ...
(Date:11/30/2015)... REDWOOD CITY, Calif. , Nov. 30, 2015 ... company that is providing innovative evidence-based solutions for the treatment ... Appeals Board (PTAB) at the U.S. Patent and Trademark Office ... (IPR) of U.S. Patent No. 8,359,102 (the ,102 patent).  ... 14, 2015, a unit of Boston Scientific Corporation filed two ...
(Date:11/30/2015)... ) has ... Market 2015-2019" report to their offering. ... of the "Orphan Drugs Market 2015-2019" ... and Markets ( ) has announced the ... report to their offering. ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... The world of ... harvesting and follicular unit extraction. These techniques and procedures have been in use for ... from hair loss. While Dr. Parsa Mohebi, M.D. has utilized many of these methods ...
(Date:11/30/2015)... Battle Creek, Michigan (PRWEB) , ... November 30, 2015 , ... ... Creek, MI, the American Cancer Society held an annual fundraising event, a 5K walk ... Recovery, a holistic treatment center for substance abuse which is also located in Battle ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals with political issues ... it a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s ... more than anyone wants to admit when it comes to how people are viewed ...
(Date:11/30/2015)... Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... star Jessie James Decker made a brave but slightly unusual choice to show her ... returning to her pre-pregnancy form may have been pre-mature. Saying that she didn’t “want ...
(Date:11/30/2015)... ... ... According to Los Angeles bariatric surgeon Michael Feiz, M.D., F.A.C.S., many of ... hunger, but instead by a hormone called ghrelin which (often prematurely) signals to ... aware that weight loss surgery can help patients lose weight by restricting the capacity ...
Breaking Medicine News(10 mins):